Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Pediatric Oncology Interventional Nutrition Therapy (POINT) Trial
NCT06175273Phase 3Completed
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyproheptadine and olanzapine in Malnutrition (4 arms). Primary endpoints: Body Composition at 6 months and Change in Body Composition Mid-Upper Arm at 6 months. Started Jan 2024; status: completed.
02
Drugs
cyproheptadineolanzapine
03
Conditions
Malnutrition
Beyond the preview
Go deeper on NCT06175273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175273.